跳至主要内容
临床试验/PER-063-20
PER-063-20尚未招募未知

MULTICENTER, RANDOMIZED, PARALLEL GROUP, DOUBLE-BLIND CLINICAL TRIAL OF SUPERIORITY IN EFFICACY AND SAFETY OF THE FIXED-DOSE COMBINATION OF CEPHALEXIN AND AMBROXOL (BIOBRONCOL®) VERSUS CEPHALEXIN IN THE TREATMENT OF ACUTE BACTERIAL PHARYNGOTONSILLITIS IN THE PEDIATRIC POPULATION.

Instituto Quimioterapico S.A.,0 个研究点目标入组 179 人开始时间: 2020年11月30日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
入组人数
179

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • - Patients between 2 - 15 years
  • - Clinical diagnosis of bacterial pharyngotonsillitis (4 or more McIsaac Modified Centor criteria) with rapid antigenic detection test for positive or negative GABHS, or less than 4 McIsaac Modified Centor criteria with positive GABHS rapid antigenic detection test.
  • - Signed informed consent form.
  • - SARS COV-2 Negative Rapid Test

排除标准

  • - Concomitant respiratory infections such as acute otitis media, acute sinusitis, pneumonia, subpharyngeal infections or tonsillar abscesses.
  • - History of rheumatic heart disease or valve dysfunction of unknown etiology
  • - Immunosuppression
  • -Skin rash
  • - Compromise of kidney or liver function.
  • - Patients with some type of cancer.
  • - History of recurrent or recent pharyngotonsillitis (more than 3 episodes in the last 6 months or 1 episode in the last month)
  • - Have received oral antibiotics in the last 7 days prior to enrollment in the study or have received cephalosporins in the last three months.
  • - History of hypersensitivity to amoxicillin or type 1 hypersensitivity to penicillin.
  • - History of hypersensitivity to ambroxol.
  • - Pregnancy or lactation.
  • - Concurrent treatment with another antibiotic or with corticosteroids.

研究者

相似试验

已完成
不适用
MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND CLINICAL TRIAL OF SUPERIORITY IN EFFICACY AND SAFETY OF THE FIXED-DOSE COMBINATION OF AMOXICILLIN AND AMBROXOL (AMBROXIL®) VERSUS AMOXICILLIN IN THE TREATMENT OF ACUTE BACTERIAL PHARYNGITIS IN THE PEDIATRIC POPULATION.
PER-062-20Instituto Quimioterapico S.A.,292
招募中
不适用
MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND, CLINICAL TRIAL OF SUPERIORITY IN EFFICACY AND SAFETY OF THE FIXED-DOSE COMBINATION OF AMOXICILLIN AND AMBROXOL (AMBROXIL®) VERSUS AMOXICILLIN IN THE TREATMENT OF ACUTE BACTERIAL PHARYNGOTONSILLITIS IN ADULTS.-J039 Acute tonsillitis, unspecifiedAcute tonsillitis, unspecifiedJ039
PER-104-20Instituto Quimioterapico S.A.,14
招募中
不适用
MULTICENTER, RANDOMIZED, PARALLEL-GROUP, DOUBLE-BLIND CLINICAL TRIAL OF SUPERIORITY IN EFFICACY AND SAFETY OF THE FIXED-DOSE COMBINATION OF CEPHALEXIN AND AMBROXOL (BIOBRONCOL®) VERSUS CEPHALEXIN IN THE TREATMENT OF ACUTE BACTERIAL PHARYNGOTONSILLITIS IN ADULTS-J039 Acute tonsillitis, unspecifiedAcute tonsillitis, unspecifiedJ039
PER-103-20Instituto Quimioterapico S.A.,25
招募中
1 期
A study to learn how bimekizumab works in children and teenagers with moderate to severe plaque psoriasisModerate to Severe Plaque PsoriasisMedDRA version: 20.0Level: LLTClassification code: 10071117Term: Plaque psoriasis Class: 10040785
CTIS2023-503859-10-00CB Biopharma168
进行中(未招募)
1 期
Clinical trial in several centers in which patients are administrating randomly in parallel with treatment or placebo (control). Neither the researchers nor the patients know which treatment the patiens are receiving. Present clinical trial evaluates safety and clinical efficacy of intradermal immunotherapy with polymerised Phleum pratense, in patients with allergic rhino-conjunctivitis with or without mild to moderate asthma, sensitized to Phleum pratense pollen.Allergic patients to the pollen of Phleum pratense with allergic rhino-conjunctivitis with or without mild to moderate asthma.MedDRA version: 16.1Level: LLTClassification code 10001728Term: Allergic rhinoconjunctivitisSystem Organ Class: 100000004853
EUCTR2014-000429-18-ESDIATER, Laboratorio de Diagnóstico y Aplicaciones Terapéuticas, S.A.174